Zealand Pharma intensifies partner hunt for other drug candidates
On Wednesday, the Danish biotech firm struck a deal with Novo Nordisk, giving the giant the commercial rights to its rescue pen, and it is now looking for similar agreements with other parties, says CEO Adam Steensberg.
by marketwire, translated by daniel pedersen
Zealand Pharma’s newly inked deal with Novo Nordisk is just one of many that the Danish biotech company intends to sign over the next few years. In March, Zealand Pharma changed its strategy to focus on research and development, choosing to let other companies take charge of future commercialization efforts.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk licenses hypoglycemia drug from Zealand Pharma
For subscribers
